ASCLETIS-B (01672) rose more than 4%, reaching HK$14.23 by the time of writing, with a trading volume of HK$26.83 million. On December 4, the CDE website showed that the marketing application for ASCLETIS's Class 1 new drug, Denifanstat tablets, had been accepted. Based on the drug's clinical research progress, Insight Database speculates that the intended indication is for moderate-to-severe acne vulgaris treatment.

Denifanstat (ASC40) is a potential first-in-class, once-daily oral fatty acid synthase (FASN) inhibitor. Originally developed by Sagimet Biosciences, ASCLETIS holds exclusive rights to the drug in Greater China.

Cinda Securities previously noted that ASCLETIS continues to invest in the weight-loss and metabolic field, focusing on core challenges with a deep pipeline layout. With potential Phase II data readouts for small-molecule GLP-1R agonists and further progress in the THRβ pipeline, the company is expected to maintain a differentiated competitive edge in the weight-loss sector. Additionally, the acne treatment drug ASC40, introduced by the company, is anticipated to gradually contribute to revenue.